Literature DB >> 7673749

Aeromonas septicaemia in Hong Kong species distribution and associated disease.

R Duthie1, T W Ling, A F Cheng, G L French.   

Abstract

During a 5-year study of 2211 patients with clinically significant positive blood cultures in Hong Kong. Aeromonas spp. were isolated in 40 cases. Among 26 episodes in which a single species was isolated. 17 (65.4%) were identified as Aeromonas hydrophila. 8 (30.8%) as A. sobria and one (3.8%) as A. caviae. There were 14 episodes with a mixture of species. Of these, nine (64.3%) were identified as A. hydrophila, two (14.3%) as A. sobria, and two (14.3%) as A. caviae. One (7.1%) was an infection with both A. sobria and A. hydrophila. These polymicrobial infections were usually combined with the presence of Enterobacteriaceae. Hepatobiliary disease was the underlying problem in 24 cases (60.0%) and malignant neoplasia in 14 (35.0%) cases. Most patients presented with fever and leucocytosis. The mortality rate for A. sobria septicaemia was not significantly different from the average rate for all septicaemias. A total of 30 isolates was available for sensitivity testing with 17 antibiotics. More than 86.0% were resistant to ampicillin, and the addition of the beta-lactamase inhibitor sulbactam did not restore its activity. All strains tested were sensitive to cefotaxime, ceftazidime, aztreonam, imipenem, norfloxacin and ciprofloxacin.

Entities:  

Mesh:

Year:  1995        PMID: 7673749     DOI: 10.1016/s0163-4453(95)90808-0

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  9 in total

1.  Bacteremia caused by Aeromonas species [corrected] complex in the Caribbean Islands of Martinique and Guadeloupe.

Authors:  Patrick Hochedez; Emilie Hope-Rapp; Claude Olive; Muriel Nicolas; Gilles Beaucaire; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Prospective nationwide study of Aeromonas infections in France.

Authors:  Brigitte Lamy; Angeli Kodjo; Frédéric Laurent
Journal:  J Clin Microbiol       Date:  2009-02-25       Impact factor: 5.948

3.  Symbiosis of Aeromonas veronii biovar sobria and Hirudo medicinalis, the medicinal leech: a novel model for digestive tract associations.

Authors:  J Graf
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  In vitro and in vivo combinations of cefotaxime and minocycline against Aeromonas hydrophila.

Authors:  W C Ko; H C Lee; Y C Chuang; S H Ten; C Y Su; J J Wu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.

Authors:  Wen-Chien Ko; Shyh-Ren Chiang; Hsin-Chun Lee; Hung-Jen Tang; Yin-Yi Wang; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Investigation of Bacteremia due to Aeromonas Species and Comparison with That due to Enterobacteria in Patients with Liver Cirrhosis.

Authors:  Toru Shizuma; Chiharu Tanaka; Hidezo Mori; Naoto Fukuyama
Journal:  Gastroenterol Res Pract       Date:  2011-12-29       Impact factor: 2.260

7.  Different clinical characteristics among Aeromonas hydrophila, Aeromonas veronii biovar sobria and Aeromonas caviae monomicrobial bacteremia.

Authors:  Han-Chuan Chuang; Yu-Huai Ho; Chorng-Jang Lay; Lih-Shinn Wang; Yeong-Shu Tsai; Chen-Chi Tsai
Journal:  J Korean Med Sci       Date:  2011-10-27       Impact factor: 2.153

8.  Clinical characteristics and risk factors of Aeromonas bloodstream infections in patients with hematological diseases.

Authors:  Chunhui Xu; Qingsong Lin; Yuanqi Zhao; Guoqing Zhu; Erlie Jiang; Shangzhu Li; Yingchang Mi; Yizhou Zheng; Fengkui Zhang; Xiaofan Zhu; Zhijian Xiao; Mingzhe Han; Jianxiang Wang; Sizhou Feng
Journal:  BMC Infect Dis       Date:  2022-03-29       Impact factor: 3.090

9.  Endogenous Aeromonas caviae Endophthalmitis: A Case Report.

Authors:  Moonkyeong Shin; Namyeong Kim; Yoonhyung Kwon
Journal:  Korean J Ophthalmol       Date:  2022-04-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.